Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MEE-SA01 + V1SA019 + V1SA020
- Development stage
- Preclinical
- Lead developer
- Hospices Civils de Lyon
- Administration
- Ophthalmic, Topical
01
Overview
MEE-SA01 + V1SA019 + V1SA020 is a novel bacteriophage cocktail consisting of three antistaphylococcal phages: MEE-SA01 (a Rosenblumvirus phage), V1SA019 (a Silviavirus phage), and V1SA020 (a Silviavirus phage). Developed through a collaboration between Massachusetts Eye and Ear, Hospices Civils de Lyon, and the French National Reference Centre for Staphylococci, this combination therapy is designed to treat severe, multidrug-resistant (MDR) methicillin-resistant *Staphylococcus aureus* (MRSA) ocular infections, including keratitis and endophthalmitis. The cocktail targets *S. aureus* by binding to wall teichoic acid (WTA) on the bacterial cell surface, leading to rapid viral replication, host cell lysis, and biofilm disruption. By combining phages from different taxonomic families (Rosenblumvirus and Silviavirus), the cocktail achieves synergistic bactericidal activity and significantly reduces the risk of resistance emergence compared to single-phage therapies or standard-of-care antibiotics like vancomycin.
- Other names
- MEE-SA01 + V1SA019 + V1SA020 phage cocktail
02
Targets
TA (Teichoic acid)
Beyond the preview
Go deeper on MEE-SA01 + V1SA019 + V1SA020.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MEE-SA01 + V1SA019 + V1SA020.